Quarterly report pursuant to Section 13 or 15(d)

License Agreements - Additional Information (Detail)

v3.3.0.814
License Agreements - Additional Information (Detail)
 3 Months Ended
Dec. 15, 2015
GBP (£)
Dec. 15, 2015
USD ($)
Oct. 16, 2012
USD ($)
Aug. 31, 2015
GBP (£)
Aug. 31, 2015
USD ($)
Jun. 30, 2016
GBP (£)
Jun. 30, 2016
USD ($)
Aug. 31, 2015
USD ($)
May. 31, 2015
USD ($)
Commitments and Contingencies [Line Items]                  
Maximum contingent payment       £ 600,000       $ 930,000  
Accrued license fees               1,860,000 $ 930,000
Annual license fee | £       £ 300,000          
Asset purchase, cash paid     $ 3,500,000            
Asset Purchase Agreement Aggregate Consideration Paying Period       10 years 10 years        
Accrued milestone payments               $ 2,500,000 $ 2,500,000
Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Royalty on every net sales       5.00%       5.00%  
Development Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Royalty on every net sales       7.50%       7.50%  
Asset Purchase Agreement Aggregate Consideration Paying Period       10 years 10 years        
Minimum annual license maintenance fees         $ 150,000        
Scenario, Forecast                  
Commitments and Contingencies [Line Items]                  
License payment £ 600,000 $ 930,000              
Maximum contingent payment           £ 600,000 $ 930,000    
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Payment to acquire other assets         1,500,000        
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Payment to acquire other assets         1,000,000        
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Payment to acquire other assets         5,000,000        
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Payment to acquire other assets         500,000        
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments                  
Commitments and Contingencies [Line Items]                  
Payment to acquire other assets         $ 500,000